重症合并2型糖尿病患者的表型共识聚类与治疗异质性分析
本研究基于MIMIC-IV数据库,对6349例重症合并2型糖尿病(CIP T2DM)患者按人口学、生理、生化参数及危重症评分行共识聚类分型,并在eICU数据库1425例中验证。识别出三种亚型:CIP T2DM-SI(死亡率16.7%,用药后血糖8.25 mmol/L)、CIP T2DM-OF(死亡率18.6%,8.03 mmol/L)、CIP T2DM-UM(死亡率8.87%,6.98 mmol/L),eICU队列组内比例分别为0.957、0.898、0.836。三种亚型在相同用药方案下院内死亡风险不同。作者认为针对亚型的个体化干预可能有助于减少不良事件并指导精准治疗。
要点
- MIMIC-IV队列(n=6349)识别出三种CIP T2DM表型,eICU队列(n=1425)组内比例0.957、0.898、0.836,显示高度一致性。
- CIP T2DM-SI(重症感染型)死亡率16.7%,用药后首次24 h血糖8.25 mmol/L。
- CIP T2DM-OF(器官衰竭型)死亡率18.6%,用药后血糖8.03 mmol/L。
- CIP T2DM-UM(监测观察型)死亡率8.87%,用药后血糖6.98 mmol/L。
- 三种亚型在相同用药方案下院内死亡风险不同,提示治疗反应存在异质性。
适用人群与场景
- 来自MIMIC-IV数据库的重症合并2型糖尿病患者(CIP T2DM),n=6349。
- 验证队列来自eICU协作研究数据库,n=1425。
研究设计与关键结果
- 研究类型:基于MIMIC-IV数据库的表型聚类分析,并在eICU数据库验证;MIMIC-IV队列n=6349,eICU队列n=1425。
- 方法:依据人口学、生理、生化参数及危重症评分,采用共识聚类算法分型,并提取高频联合用药方案分析亚型间治疗异质性。
- 识别三种亚型:CIP T2DM-SI(重症感染型)死亡率16.7%、用药后血糖8.25 mmol/L;CIP T2DM-OF(器官衰竭型)死亡率18.6%、8.03 mmol/L;CIP T2DM-UM(监测观察型)死亡率8.87%、6.98 mmol/L。
- eICU队列组内比例分别为0.957、0.898、0.836,显示高度一致性。
- 三种亚型在相同用药方案下院内死亡风险不同。
证据类型、等级与局限
- 证据类型:基于MIMIC-IV与eICU数据库的聚类分析研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,针对这些亚型的个体化干预可能有助于减少不良事件并指导实践中的精准治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIMS: This study aimed to establish a phenotypic clustering model for critically ill patients with comorbid type 2 diabetes mellitus (CIP T2DM), define distinct subtypes, and analyze differences in clinical characteristics and treatment response.
METHODS: Patients from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database were phenotyped based on demographic, physiological, and biochemical parameters, along with critically ill scores, using a consensus clustering algorithm. Subtype validity was assessed using the eICU Collaborative Research Database (eICU). High-frequency combination drug regimens were then extracted to reveal therapeutic heterogeneity among subtypes.
RESULTS: Three subtypes were identified in the MIMIC-IV cohort (n = 6349). The in-group proportions of 0.957, 0.898, and 0.836 in the eICU cohort (n = 1425) show high consistency. These three subtypes are: a) CIP T2DM with severe infection (CIP T2DM-SI) with a mortality of 16.7% and a post-medication blood glucose (PMBG, first measured 24 h after medication administration) of 8.25 mmol/L; b) CIP T2DM with organ failure (CIP T2DM-OF) with 18.6% mortality and 8.03 mmol/L PMBG; and c) CIP T2DM under monitoring for continuous observation and evaluation (CIP T2DM-UM) with 8.87% mortality and 6.98 mmol/L PMBG. Moreover, the three subtypes showed different in-hospital mortality risks under the same medication regimen.
CONCLUSIONS: Three phenotypes were identified in CIP T2DM, showing significant heterogeneity in clinical characteristics and prognosis. Personalized interventions for these subtypes may help reduce adverse events and guide precise treatment in practice.
参考来源
- Chen X, Sun J, Li H, et al. Phenotypic Consensus Clustering and Treatment Heterogeneity Analysis in Critically Ill Patients with Comorbid Type 2 Diabetes Mellitus. Arch Med Res. 2025. PMID: 40068482. doi:10.1016/j.arcmed.2025.103197
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。